SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Wahlin A) "

Sökning: WFRF:(Wahlin A)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
31.
  • Efe, Cumali, et al. (författare)
  • Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis
  • 2018
  • Ingår i: Digestive Diseases and Sciences. - : SPRINGER. - 0163-2116 .- 1573-2568. ; 63:5, s. 1348-1354
  • Tidskriftsartikel (refereegranskat)abstract
    • We studied the efficacy and safety of mycophenolate mofetil (MMF) and tacrolimus as second-line therapy in pediatric patients with autoimmune hepatitis (AIH) who were intolerant or non-responders to standard therapy (corticosteroid and azathioprine). We performed a retrospective study of data from 13 centers in Europe, USA, and Canada. Thirty-eight patients (< 18 years old) who received second-line therapy (18 MMF and 20 tacrolimus), for a median of 72 months (range 8-182) were evaluated. Patients were categorized into two groups: Group 1 (n = 17) were intolerant to corticosteroid or azathioprine, and group 2 (n = 21) were non-responders to standard therapy. Overall complete response rates were similar in patients treated with MMF and tacrolimus (55.6 vs. 65%, p = 0.552). In group 1, MMF and tacrolimus maintained a biochemical remission in 88.9 and 87.5% of patients, respectively (p = 0.929). More patients in group 2 given tacrolimus compared to MMF had a complete response, but the difference was not statistically significant (50.0 vs. 22.2%, p = 0.195). Biochemical remission was achieved in 71.1% (27/38) of patients by tacrolimus and/or MMF. Decompensated cirrhosis was more commonly seen in MMF and/or tacrolimus non-responders than in responders (45.5 vs. 7.4%, p = 0.006). Five patients who received second-line therapy (2 MMF and 3 tacrolimus) developed side effects that led to therapy withdrawal. Long-term therapy with MMF or tacrolimus was generally well tolerated by pediatric patients with AIH. Both MMF and tacrolimus had excellent efficacy in patients intolerant to corticosteroid or azathioprine. Tacrolimus might be more effective than MMF in patients failing previous therapy.
  •  
32.
  •  
33.
  •  
34.
  •  
35.
  • Juliusson, Gunnar, et al. (författare)
  • Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival.
  • 2006
  • Ingår i: Leukemia. - : Nature Publishing Group. - 1476-5551 .- 0887-6924. ; 20:1, s. 42-7
  • Tidskriftsartikel (refereegranskat)abstract
    • Combination chemotherapy may induce remission from acute myeloid leukemia (AML), but validated criteria for treatment of elderly are lacking. The remission intention ( RI) rate for elderly patients, as reported to the Swedish Leukemia Registry, was known to be different when comparing the six health care regions, but the consequences of different management are unknown. The Leukemia Registry, containing 1672 AML patients diagnosed between 1997 and 2001, with 98% coverage and a median follow-up of 4 years, was completed with data from the compulsory cancer and population registries. Among 506 treated and untreated patients aged 70-79 years with AML (non-APL), there was a direct correlation between the RI rate in each health region ( range 36-76%) and the two-year overall survival, with no censored observations (6-21%) ( v 2 for trend = 11.3, P < 0.001; r(2) = 0.86, P < 0.02, nonparametric). A 1-month landmark analysis showed significantly better survival in regions with higher RI rates ( P = 0.003). Differences could not be explained by demographics, and was found in both de novo and secondary leukemias. The 5-year survival of the overall population aged 70-79 years was similar between the regions. Survival of 70-79-year-old AML patients is better in regions where more elderly patients are judged eligible for remission induction.
  •  
36.
  •  
37.
  •  
38.
  •  
39.
  •  
40.
  •  
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (154)
konferensbidrag (48)
bokkapitel (2)
recension (2)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (148)
övrigt vetenskapligt (59)
Författare/redaktör
Wahlin, A (99)
Backman, L (34)
Winblad, B (25)
Wahlin, S. (23)
Wahlin, TBR (16)
Efe, C (12)
visa fler...
Purnak, T (11)
Amer-Wahlin, I (10)
Ozaslan, E (10)
Fastbom, J (8)
Lehmann, S (7)
Brune, M (7)
Kimby, E (7)
Juliusson, G (7)
Bjorkholm, M (7)
Lundin, A (7)
Hill, RD (7)
Fahlander, K (7)
Turesson, I (6)
Tidefelt, U (6)
Fratiglioni, L (6)
Hoglund, M (6)
Bäckman, Lars (6)
Kwee, A (6)
Dixon, RA (6)
Wahlin, B (6)
Larsson, M (5)
Ljungman, P (5)
Hagglund, H (5)
Nilsson, E (5)
Sander, B (5)
Landgren, O (5)
Simonsson, B. (5)
Stenberg, A (5)
Nilsson, LG (5)
Werner, M. (4)
Malm, C (4)
Forsell, Y (4)
Eriksson, M (4)
Remberger, M. (4)
Mollgard, L (4)
Harper, P (4)
Tedeschi, A (4)
Wahlin, Åke (4)
Billstrom, R (4)
Kristinsson, SY (4)
Lackgren, G (4)
Berg, T. (4)
Cohen, A (4)
Antunovic, P. (4)
visa färre...
Lärosäte
Karolinska Institutet (147)
Uppsala universitet (29)
Umeå universitet (24)
Lunds universitet (16)
Göteborgs universitet (11)
Stockholms universitet (8)
visa fler...
Linköpings universitet (6)
Kungliga Tekniska Högskolan (3)
Örebro universitet (3)
Jönköping University (3)
Malmö universitet (2)
Mälardalens universitet (1)
Linnéuniversitetet (1)
Marie Cederschiöld högskola (1)
visa färre...
Språk
Engelska (205)
Svenska (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (41)
Naturvetenskap (6)
Samhällsvetenskap (6)
Teknik (3)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy